ZYUS Life Sciences Past Earnings Performance
Past criteria checks 0/6
ZYUS Life Sciences's earnings have been declining at an average annual rate of -11.1%, while the Pharmaceuticals industry saw earnings growing at 31.5% annually. Revenues have been growing at an average rate of 41.7% per year.
Key information
-11.1%
Earnings growth rate
-3.8%
EPS growth rate
Pharmaceuticals Industry Growth | 23.1% |
Revenue growth rate | 41.7% |
Return on equity | -184.3% |
Net Margin | -12,134.2% |
Last Earnings Update | 31 Dec 2023 |
Recent past performance updates
Revenue & Expenses BreakdownBeta
How ZYUS Life Sciences makes and spends money. Based on latest reported earnings, on an LTM basis.
Earnings and Revenue History
Date | Revenue | Earnings | G+A Expenses | R&D Expenses |
---|---|---|---|---|
31 Dec 23 | 0 | -43 | 13 | 1 |
30 Sep 23 | 0 | -24 | 11 | 1 |
30 Jun 23 | 0 | -27 | 10 | 1 |
31 Mar 23 | 0 | -24 | 9 | 2 |
31 Dec 22 | 0 | -25 | 10 | 2 |
30 Sep 22 | 0 | -26 | 10 | 3 |
31 Dec 21 | 0 | -23 | 13 | 5 |
Quality Earnings: ZYUS is currently unprofitable.
Growing Profit Margin: ZYUS is currently unprofitable.
Free Cash Flow vs Earnings Analysis
Past Earnings Growth Analysis
Earnings Trend: Insufficient data to determine if ZYUS's year-on-year earnings growth rate was positive over the past 5 years.
Accelerating Growth: Unable to compare ZYUS's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZYUS is unprofitable, making it difficult to compare its past year earnings growth to the Pharmaceuticals industry (22%).
Return on Equity
High ROE: ZYUS has a negative Return on Equity (-184.26%), as it is currently unprofitable.